Literature DB >> 17276177

Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.

Karim El Harchaoui1, Wim A van der Steeg, Erik S G Stroes, Jan Albert Kuivenhoven, James D Otvos, Nicholas J Wareham, Barbara A Hutten, John J P Kastelein, Kay-Tee Khaw, S Matthijs Boekholdt.   

Abstract

OBJECTIVES: We assessed relations of low-density lipoprotein (LDL) particle number (LDL-P) and LDL particle size as measured by nuclear magnetic resonance spectroscopy with LDL cholesterol (LDL-C) and the risk of future coronary artery disease (CAD).
BACKGROUND: Whereas LDL-C is an established risk factor for CAD, its discriminative power is limited. Measuring LDL-P and size may have stronger associations with CAD than LDL-C.
METHODS: A nested case-control study was performed in the prospective EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk study, which comprises 25,663 subjects. Cases (n = 1,003) were individuals who developed CAD during 6 year follow-up. Control subjects (n = 1,885) were matched for age, gender, and enrollment time. Odds ratios (ORs) for future CAD were calculated, and we also evaluated whether LDL-P could improve the Framingham risk score (FRS) to predict CAD.
RESULTS: In univariate analyses, LDL-P (OR 2.00, 95% confidence interval [CI] 1.58 to 2.59) and non-high-density lipoprotein cholesterol (non-HDL-C) (OR 2.14, 95% CI 1.69 to 2.69) were more closely associated with CAD than LDL-C (OR 1.73, 95% CI 1.37 to 2.18). The additional value of LDL-P was lost after adjustment for HDL-C and triglyceride levels. Whereas LDL size was inversely related to CAD (OR 0.60, 95% CI 0.47 to 0.76), this relation was abolished upon adjustment for LDL-P. In a model adjusted for the FRS, LDL-P retained its association with CAD (p for trend 0.02).
CONCLUSIONS: In this large study of individuals with moderately elevated LDL-C, LDL-P was related to CAD on top of FRS as well as after adjusting for LDL-C. The additional value of LDL-P was comparable to non-HDL-C, and it was abolished after adjusting for triglycerides and HDL-C.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17276177     DOI: 10.1016/j.jacc.2006.09.043

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  89 in total

1.  Lipoprotein subfractions and particle size in end-stage renal disease.

Authors:  Peter A McCullough; Fawaz Al-Ejel; Robert C Maynard
Journal:  Clin J Am Soc Nephrol       Date:  2011-12       Impact factor: 8.237

2.  Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study.

Authors:  Jean-Claude Ansquer; Christophe Corda; Karine Le Malicot; Valerie Jessent
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

Review 3.  Lipid parameters for measuring risk of cardiovascular disease.

Authors:  Benoit J Arsenault; S Matthijs Boekholdt; John J P Kastelein
Journal:  Nat Rev Cardiol       Date:  2011-02-01       Impact factor: 32.419

4.  HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study.

Authors:  Phyllis C Tien; Michael F Schneider; Christopher Cox; Mardge Cohen; Roksana Karim; Jason Lazar; Mary Young; Marshall J Glesby
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

Review 5.  Is it LDL particle size or number that correlates with risk for cardiovascular disease?

Authors:  H Robert Superko; Radhika R Gadesam
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

6.  The genetic architecture of lipoprotein subclasses in Gullah-speaking African American families enriched for type 2 diabetes: the Sea Islands Genetic African American Registry (Project SuGAR).

Authors:  Jasmin Divers; Michèle M Sale; Lingyi Lu; Wei-Min Chen; Kerry H Lok; Ida J Spruill; Jyotika K Fernandes; Carl D Langefeld; W Timothy Garvey
Journal:  J Lipid Res       Date:  2009-09-25       Impact factor: 5.922

Review 7.  Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease.

Authors:  William C Cromwell; Thomas A Barringer
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

8.  Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy.

Authors:  Monique A Ford; Joseph P McConnell; Shahar Lavi; Charanjit S Rihal; Abhiram Prasad; Gurpreet S Sandhu; Stacy J Hartman; Lilach O Lerman; Amir Lerman
Journal:  Atherosclerosis       Date:  2009-05-06       Impact factor: 5.162

9.  A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.

Authors:  D C Henderson; X Fan; B Sharma; P M Copeland; C P Borba; R Boxill; O Freudenreich; C Cather; A Eden Evins; D C Goff
Journal:  Acta Psychiatr Scand       Date:  2009-01-12       Impact factor: 6.392

10.  Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy.

Authors:  David J Decewicz; David M Neatrour; Amy Burke; Mary Jane Haberkorn; Heather L Patney; Marina N Vernalis; Darrell L Ellsworth
Journal:  Lipids Health Dis       Date:  2009-06-29       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.